Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Smith & Nephew Snats ( (SNN) ) is now available.
On August 20, 2025, Sybella Stanley, a Non-Executive Director at Smith & Nephew plc, purchased 1,520 ordinary shares of the company on the London Stock Exchange. This transaction was part of the company’s policy to compensate its non-executive directors partially in shares, reflecting a strategic alignment of management interests with shareholder value.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the most significant factors driving the score. The stock’s bullish technical indicators are tempered by overbought signals, and the valuation suggests it may be overvalued. Despite challenges in emerging markets and potential tariff impacts, the company’s strategic initiatives and share buyback plan reflect confidence in sustaining growth.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company based in Watford, England. The company specializes in advanced wound management, orthopedics, and sports medicine products, serving healthcare professionals and patients worldwide.
Average Trading Volume: 982,596
Technical Sentiment Signal: Buy
Current Market Cap: $16.05B
See more data about SNN stock on TipRanks’ Stock Analysis page.